This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

The Protective Effects Of Treatment With Hyperbaric Oxygen Prior To Bypass Heart Surgery

This study has been completed.
Sponsor:
Collaborator:
North of England Medical & Hyperbaric Services
Information provided by:
Hull and East Yorkshire Hospitals NHS Trust
ClinicalTrials.gov Identifier:
NCT00623142
First received: February 14, 2008
Last updated: February 22, 2008
Last verified: January 2008
  Purpose
The purpose of this study was to determine if treating patients who have coronary heart disease with hyperbaric oxygen (HBO) prior to coronary artery bypass graft (CABG) surgery reduces injury to the heart and vascular system during and after surgery. Furthermore, this study also aims to identify some of the post CABG clinical effects of HBO treatment prior to CABG.

Condition Intervention Phase
Myocardial Reperfusion Injury Cytoprotection Drug: Hyperbaric Oxygen Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Care Provider)
Primary Purpose: Health Services Research
Official Title: The Effects of Hyperbaric Oxygen Preconditioning On Cardiovascular Protection & Ischemic Reperfusion Injury

Resource links provided by NLM:


Further study details as provided by Hull and East Yorkshire Hospitals NHS Trust:

Primary Outcome Measures:
  • Myocardial Hsp72 protein [ Time Frame: Intra-operative (During CABG) ]
  • Myocardial eNOS protein [ Time Frame: Intra-Operative (During CABG) ]
  • Serum Troponin-T [ Time Frame: Peri-operative ]
  • Serum soluble ICAM-1 [ Time Frame: Peri-operative ]
  • Serum soluble PSGL-1 [ Time Frame: Peri-operative ]
  • Serum soluble P-Selectin [ Time Frame: Peri-operative ]
  • Serum soluble E-Selectin [ Time Frame: Peri-operative ]

Secondary Outcome Measures:
  • All cardiovascular haemodynamic parameters as measured by a pulmonary artery catheter [ Time Frame: Peri-operative ]
  • Duration of mechanical ventilation [ Time Frame: Post Operative ]
  • Duration of endotracheal intubation [ Time Frame: post operative ]
  • Length of stay in ICU [ Time Frame: Post-operative ]
  • Blood loss [ Time Frame: Post operative ]
  • Inotrope usage [ Time Frame: Post operative ]
  • Atrial Fibrillation [ Time Frame: Post operative ]
  • Low cardiac output status [ Time Frame: Post operative ]
  • Pulmonary complications [ Time Frame: Post operative ]
  • Renal Complications [ Time Frame: Post operative ]
  • Cerebrovascular complications [ Time Frame: Post operative ]
  • Gastrointestinal complications [ Time Frame: Post operative ]
  • Wound complications [ Time Frame: Post operative ]
  • Cost of ICU stay [ Time Frame: Post operative ]

Enrollment: 81
Study Start Date: January 2005
Study Completion Date: January 2008
Primary Completion Date: January 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: A
Patients in this arm were not treated with HBO prior to CABG
Experimental: B
Patients in this arm were treated with HBO prior to CABG
Drug: Hyperbaric Oxygen
100% Oxygen at 2.4 ATA for 30 minutes followed by 5 minutes break followed by 100% Oxygen at 2.4 ATA for another 30 minutes. This intervention was given about 4 to 5 hours prior to CABG
Other Name: Hyperbaric Oxygen Preconditioning

  Eligibility

Ages Eligible for Study:   20 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients undergoing elective first time CABG
  • Patients with at least 1 vessel coronary artery disease undergoing on- pump CABG

Exclusion Criteria:

  • Age ≤ 20 years or ≥ 85 years
  • Ejection fraction < 30%
  • Unstable angina
  • Recent myocardial infarction (< 1 month)
  • Any additional cardiac disease (e.g. arrythmia, aneurysm, valvular/septal disease, dissection or elevated pulmonary artery pressure)
  • Any end stage organ failure (e.g. renal and respiratory failure)
  • History of chronic obstructive pulmonary disease (COPD)
  • Pneumothorax
  • Pulmonary bullae
  • Convulsions
  • Current history of malignancy
  • Severe myopia or intraocular lens
  • Patients on K+(ATP) Channel Openers e.g. Nicorandil, Oral Hypoglycemics, Opioid Analgesics, Catecholamines.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00623142

Locations
United Kingdom
Hull & East Yorkshire NHS Trust (Castle Hill Hospital)
Hull, East Riding of Yorkshire, United Kingdom, HU16 5JQ
Sponsors and Collaborators
Hull and East Yorkshire Hospitals NHS Trust
North of England Medical & Hyperbaric Services
Investigators
Principal Investigator: Jeysen Z Yogaratnam, MB.BCh, BAO, MRCS Hull & East Yorkshire NHS Trust (Castle Hill Hospital), United Kingdom
  More Information

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Dr. Jeysen Zivan Yogaratnam, Hull & East Yorkshire NHS Trust
ClinicalTrials.gov Identifier: NCT00623142     History of Changes
Other Study ID Numbers: R0047
04/Q1104/26
Study First Received: February 14, 2008
Last Updated: February 22, 2008

Keywords provided by Hull and East Yorkshire Hospitals NHS Trust:
Myocardial protection
Ischemic Reperfusion Injury
Hyperbaric Oxygen
Preconditioning

Additional relevant MeSH terms:
Reperfusion Injury
Myocardial Reperfusion Injury
Vascular Diseases
Cardiovascular Diseases
Postoperative Complications
Pathologic Processes
Cardiomyopathies
Heart Diseases
Myocardial Ischemia

ClinicalTrials.gov processed this record on August 18, 2017